Article info
PDFCommentary
Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem
- Correspondence to Dr Ana Santos Rutschman, Institute for Vaccine Science and Policy, Saint Louis University, Saint Louis, Missouri, USA; ana.rutschman{at}slu.edu
Citation
Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem
Publication history
- First published February 9, 2022.
Online issue publication
July 11, 2022
Article Versions
- Previous version (10 March 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.